Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Japan’s Healthcare Spending Reaches 48.1 Trillion Yen in FY2023
October 14, 2025
- PMDA Lays Out AI Action Plan, Eyes Specialized In-House System
October 14, 2025
- MHLW Panel OKs 19th Edition of Japanese Pharmacopoeia; 27 New Products Added
October 14, 2025
- MHLW Maps Out Action Plan to Tackle Drug Supply Disruptions
October 14, 2025
- Eto to Stay as LDP Pharma Study Group Chair Even After Exiting Politics
October 10, 2025
- GS1 Barcode Adoption Stalls at 40% of Hospitals, Pharmacist Urges Subsidies
October 10, 2025
- MHLW to Disclose Review Reports for Conditionally Cleared Regenerative Therapies Even If Full Approval Bid Dropped
October 10, 2025
- Japan Launches Study on Legal Framework for Patent Linkage System
October 9, 2025
- Chuikyo Frowns on Industry Calls for Scrapping Huge-Seller Re-Pricing, Spillovers
October 9, 2025
- Chuikyo Wary of Revising “Zero” Premium Rule for Low Cost Disclosure
October 9, 2025
- Komeito Calls for Careful Study of Re-Pricing Rules for CAR-T Therapies
October 9, 2025
- Elevidys Coverage Debate to Resume after MHLW Gains Broad Understanding on Safety
October 9, 2025
- Japan Begins Overhaul of Patent Linkage Framework with First Notification
October 8, 2025
- Japan Panel OKs Basic Policy for Stockpiling Crisis-Response Medicines
October 8, 2025
- Turn Sakaguchi’s Nobel-Winning Research into Societal Impact: LDP Panel Chief
October 8, 2025
- Takaichi Vows Hospital Support via Extra Budget; MHLW Sees Boost for Funding Requests
October 7, 2025
- Japan to Allow Vaccine Strain Changes Under PACMP Framework
October 6, 2025
- Japan Health Minister Mum on NIP Use of RSV Preventives for Children
October 6, 2025
- Panel Split on Delisting OTC-Like Drugs from Insurance Coverage
October 3, 2025
- SanBio’s Akuugo Set for Re-Review on Oct. 16, Shipment Decision Nears
October 3, 2025
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…